Paracrine cytokine adjuvants in cancer immunotherapy

Annual Review of Immunology

Volumn 13, Issue , 1995, Pages 399-415

  Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

immunotherapy; paracrine cytokine adjuvants

Indexed keywords

CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; CANCER; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0028908324     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.iy.13.040195.002151     Document Type: Review

References (63)

1. Berd D, Maguire HC, Mastrangelo MJ. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46:2572-79
2. Livingston PO, Albino AP, Cheng TJC. 1985. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55:713-19
3. Berd D, Maguire HC, McCue P. 1990. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 8:1858-63
4. McCune CS, O'Donnell RW, Marquis DM. 1990. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32:62-67
5. van der Bruggen PC, Traversari C, Chomez P, Lurquin C, DePlaen E, Van den Eynde B, Knuth A, Boon T. 1991. A gene encoding an antigen recognized cytotoxic T lymphocytes on a human melanoma. Science 254:1643-50
6. Brichard V, Van Pel A, Wolfel T, Wolfel C, DePlaen, E, Lethe B, Coolie P, Boon T. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-95
7. Gaughler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921-30
8. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-9
9. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg S. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515-19
10. Coulie P, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, DePlaen E, Lurquin C, Szikora J-P, Renauld J-C, Boon T. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42
11. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingloff CL. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science 264:716-19
12. Rosenberg SA. 1991. Immunotherapy and gene therapy of cancer. Cancer Res. 51:5074-79
13. Lafreniere R, Rosenberg SA. 1985. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J. Immunol. 135:4273-80
14. Papa MZ, Mule JJ, Rosenberg SA. 1986. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interteukin-2 in vivo; immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res. 46:4973-78
15. Rosenberg SA. 1988. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In Important Advances in Oncology, ed. V DeVita, S Hellman, SA Rosenberg, pp. 217-257. Philadelphia: JB Lippincott
16. Rosenberg SA, Lotze MT, Yang JC, Aebersold PA, Lineham, WM Seipp CA, White DE. 1989. Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann. Surg. 210:474-85
17. Lindenmann J, Klein P. 1967. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J. Exp. Med. 126:93-99
18. Lehner D, Schlag R, Liebrich W, Schirrmacher V. 1990. Postoperative active specific immunization of curatively resected colorectal cancer patients with a virus modified autologous tumor cell vaccine. Cancer Immunol. Immunother. 32:173-78
19. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P. 1988. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 38:2975-80
20. d). Cancer Res. 47:3136-41
21. Plautz G, Yang Z-Y, Wu B-Y. 1993. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA 90:4645-51
22. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J, Karasuyama H, Vogelstein B, Frost P. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-03
23. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. 1990. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217-24
24. Tepper R, Pattengale P, Leder P. 1989. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503-12
25. Golumbek P, Lazenby A, Levitsky H, Jaffee L, Karasuyama H, Baker M, Pardoll DM. 1991. Treatment of established renal cancer by tumor cells engineered to secrete Interleukin-4. Science 254:713-16
26. Colombo M, Modesti A, Parmiani G, Forni G. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853-57
27. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA, McIntyre BW. 1992. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium association with expression of VCAM-1. J. Immunol. 148:1086-92
28. Tepper RI, Coffman RL, Leder P. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257:548-51
29. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. 1993. Interleukin 3 enhances development of tumor-reactive cytotoxic T cells by a CD4-dependent mechanism. Cancer Res. 53:2112-17
30. Karp SE, Farber A, Salo JC, Hwu P, Jaffee G, Asher A, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA. 1993. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J. Immunol. 150:896-908
31. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hirofumi H, Pardoll D, Mulligan RC. 1993. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting antitumor immunity. Proc. Natl. Acad. Sci. USA 90:3539-43
32. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-81
33. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Scholer G. 1992. Identification of proliferating dendritic cell precursors in mouse blood. J. Exp. Med. 175:1157-67
34. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-702
35. Caix C, Dezitter-Dambuyant C, Schmitt D, Banchereau J. 1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-60
36. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockerbacher B, Konwalinka G, Fritsch O, Steinman RM, Schuler G. 1994. Proliferating dendritic cell progenitors in human Wood. J. Exp. Med.. 180:83-93
37. Salusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J. Exp. Med. 179:1109-18
38. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll DM, Levitsky H. 1994. The role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-65
39. Rock KL, Rothstein L, Gamble S, Flieschacker C. 1993. Characterization of APCs that present exogenous antigens in association with class I MHC molecules. J. Immunol. 150:438-42
40. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. 1993. Pagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359-62
41. Langer R. 1990. New methods of drug delivery. Science 249:1527-31
42. Golumbek PT, Azhari R, Jaffe EM, Levitsky, Lazenby A, Leong K, Pardoll DM. 1993. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 53:5841-44
43. Alfonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-37
44. Mulligan RC. 1993. The basic science of gene therapy. Science 260:926-32
45. Miller AD. 1992. Gene therapy. Nature 357:455-60
46. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. 1992. Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA 89:2581-84
47. Rosenfeld MA, Siegfried W, Yoshimura K, Perricaudet LD, Crystal RG. 1991. Adenovirus mediated transfer of a recombinant a-1 antitrypsin gene to the lung epithelium. Science 252:431-34
48. Jaffee EM, Lazenby A, Pardoll DM. 1994. Murine models of genetically-altered tumor vaccines for use in designing phase I gene-targeted immunotherapy trials. Submitted
49. Witmer-Pack MD, Olivier W, Valinsky J, Schuler G, Steinman RM. 1987. GM-CSF is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166:1484-95
50. Heufler C, Koch F, Schuler G. 1987. GM-CSF and IL-1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167:700-12
51. Bubenik J, Simova J, Jandlova T. 1990. Immunotherapy of cancer using local administration of lymphoid cells expressing IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23:287-89
52. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149:3627-34
53. Bannerji R, Arroyo CD, Cordon-Cordo C. 1994. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 152:2324-40
54. Li W, Diamenstein T, Blankenstein B. 1990. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol. 27:1331-39
55. Watanabe V, Kuribayashi K, Miyatake S. 1989. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc. Natl. Acad. Sci. USA 86:9456-62
56. Gansbacher B, Bannerji R, Daniels B. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820-25
57. + T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175:1423-28
58. Asher A, Mule J, Kasid A. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J. Immunol. 146:3227-34
59. Blankenstein T, Qin Z, Uberla K. 1991.Tumor supression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173:1047-52
60. Porgador A, Tzehoval E, Katz A. 1992. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:3679-87
61. + T cell-dependent tumor rejection. J. Exp. Med. 174:1291-99
62. Rollins B, Sunday M. 1991. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol. Cell Biol. 11:3125-32
63. Colombo M, Ferrari G, Stoppacciaro A. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889-95